EUCTR2013-005394-45-ES进行中(未招募)1 期
Dermatophagoides pteronyssinus and Dermatophagoides farinae allergen extract. Determination of the allergenic potency in vivo histamine equivalent units (HEP)
Inmunotek, S.L.0 个研究点目标入组 23 人开始时间: 2015年7月10日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 23
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Clinical history positive inhalation allergy (rhinitis I rhinoconjunctivitis I asthma) against Dermatophagoides pteronyssinus or Dermatophagoides farinae.
- •-A prick-test positive (average of the papule ? 3 mm diameter) with a summary of the same allergen I presence against the allergen specific IGE.
- •-The average area of the papule obtained by histamine dihydrochloride to 10 mgml must be greater than or equal 7 mm2.
- •-Age: over 18 years of age.
- •-Both sexes.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Subjects outside of the age range.
- •-Individuals who have previously received immunotherapy in the last 5 years for the treatment of asthma or the allergic rhinoconjunctivitis induced by allergens that may interfere with the extract mixture of Dermatophagoides pteronyssinus or farinae.
- •-Subjects with important symptoms of rhinoconjunctivitis I bronchial asthma in which the suspension of the antihistamine treatment for systemic is contraindicated.
- •-Subjects that have previously submitted a serious secondary reaction during skin prick test diagnostic tests.
- •-Subjects in treatment with ss-blockers.
- •-Unstable subjects of clinical point of view (asthma acute, febrile, etc.).
- •-Subjects with lesions of active hives, severe active dermographism, severe atopic dermatitis, sunburn, eczema, lesions of psoriasis in the area of realization of the prick test (risk of false positives).
- •-Subjects with viral infection activates the herpes simplex or herpes varicella-zoster in the area of realization of the prick test.
- •-Subjects that have some pathology in which the administration of adrenaline (hyperthyroidism, hypertension, heart disease, etc.) is contraindicated.
- •-States of the subject that can not offer cooperation and severe psychiatric disorders.
- •-Pregnant or women at risk of pregnancy and breastfeeding women.
研究者
相似试验
已完成
不适用
Biological Stardadization of D. Pteronyssinus and D. Farinae Allergen ExtractsImmune System DiseasesNCT02527122Inmunotek S.L.30
已完成
2 期
Efficacy of VALERGEN-DP sublingual vaccine in asthmatic adults.AsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessBronchial asthmaRPCEC00000034ational Biopreparations Center (BIOCEN)
已完成
2 期
Efficacy of VALERGEN-DP subcutaneous vaccine in asthmatic adultsBronchial asthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessAsthmaRPCEC00000027ational Biopreparations Center (BIOCEN)
已完成
2 期
Evidence of the clinical efficacy of VALERGEN-DP vaccine in asthmaticsAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessBronchial asthmaRPCEC00000037ational Biopreparations Center (BIOCEN)
已完成
2 期
Biological Standardization of Dermatophagoides Pteronyssinus Allergen ExtractAllergy Dermatophagoides PteronyssinusAllergic AsthmaAllergic RhinitisNCT01821716Laboratorios Leti, S.L.42
